{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03118986",
            "orgStudyIdInfo": {
                "id": "1000053716"
            },
            "organization": {
                "fullName": "The Hospital for Sick Children",
                "class": "OTHER"
            },
            "briefTitle": "RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy",
            "officialTitle": "Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Highly Emetogenic Chemotherapy",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Pediatrics",
                "Other"
            ],
            "study": "rct-of-olanzapine-for-control-of-civ-in-children-receiving-highly-emetogenic-chemotherapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2017-08-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2017-03-16",
            "studyFirstSubmitQcDate": "2017-04-13",
            "studyFirstPostDateStruct": {
                "date": "2017-04-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Lee Dupuis",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "The Hospital for Sick Children"
            },
            "leadSponsor": {
                "name": "The Hospital for Sick Children",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "University of California, San Francisco",
                    "class": "OTHER"
                },
                {
                    "name": "Children's Mercy Hospital Kansas City",
                    "class": "OTHER"
                },
                {
                    "name": "St. Justine's Hospital",
                    "class": "OTHER"
                },
                {
                    "name": "Columbia University",
                    "class": "OTHER"
                },
                {
                    "name": "Medical University of South Carolina",
                    "class": "OTHER"
                },
                {
                    "name": "CancerCare Manitoba",
                    "class": "OTHER"
                },
                {
                    "name": "University of North Carolina, Chapel Hill",
                    "class": "OTHER"
                },
                {
                    "name": "Nationwide Children's Hospital",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy"
        },
        "conditionsModule": {
            "conditions": [
                "Vomiting in Infants and/or Children",
                "Nausea",
                "Hematopoietic System--Cancer",
                "Oncology"
            ],
            "keywords": [
                "olanzapine",
                "vomiting",
                "children",
                "adolescents",
                "bone marrow transplant",
                "supportive care"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Olanzapine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Standard antiemetics plus olanzapine",
                    "interventionNames": [
                        "Drug: Olanzapine"
                    ]
                },
                {
                    "label": "Placebo Oral Tablet",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Standard antiemetics plus placebo",
                    "interventionNames": [
                        "Drug: Placebo Oral Tablet"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Olanzapine",
                    "description": "olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight",
                    "armGroupLabels": [
                        "Olanzapine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo Oral Tablet",
                    "description": "Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine",
                    "armGroupLabels": [
                        "Placebo Oral Tablet"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Rate of CIV control during the acute phase",
                    "description": "Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase",
                    "timeFrame": "up to 8 days"
                },
                {
                    "measure": "Rate of CIV control during the acute phase",
                    "description": "Partial control is defined as no more than two vomits or retches during any 24-hr period",
                    "timeFrame": "up to 8 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "complete and partial CINV control",
                    "description": "Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase, Partial control is defined as no more than two vomits or retches during any 24-hr period",
                    "timeFrame": "up to 1 month"
                },
                {
                    "measure": "Safety profile of olanzapine based on toxicities",
                    "description": "Based on descriptive statistics on reported toxicities.",
                    "timeFrame": "up to 1 month"
                },
                {
                    "measure": "Safety profile of olanzapine based on weight",
                    "description": "Based on descriptive statistics on reported body weight",
                    "timeFrame": "up to 1 month"
                },
                {
                    "measure": "Safety profile of olanzapine based on Pediatric Adverse Event Rating Scale (PAERs)",
                    "description": "Based on descriptive statistics on reported PAERs, will describe the most reported and most bothersome adverse events reported in the PAERs questionnaire.",
                    "timeFrame": "up to 1 month"
                },
                {
                    "measure": "Safety profile of olanzapine based on prolactin",
                    "description": "Based on descriptive statistics on reported prolactin, will report incidence of abnormal prolactin values comparing the two arms",
                    "timeFrame": "up to 1 month"
                },
                {
                    "measure": "Safety profile of olanzapine based on amylase",
                    "description": "Based on descriptive statistics on reported amylase, will report incidence of abnormal amylase values comparing the two arms",
                    "timeFrame": "up to 1 month"
                },
                {
                    "measure": "Safety profile of olanzapine based on creatine phophotase",
                    "description": "Based on descriptive statistics on reported creatine phophotase, will report incidence of abnormal creatine phophotase values comparing the two arms",
                    "timeFrame": "up to 1 month"
                },
                {
                    "measure": "Safety profile of olanzapine based on triglycerides",
                    "description": "Based on descriptive statistics on reported triglycerides, will report incidence of abnormal triglyceride values comparing the two arms",
                    "timeFrame": "up to 1 month"
                },
                {
                    "measure": "Impact of olanzapine on HSCT outcomes on incidence of veno-occlusive disease",
                    "description": "Looking at incidence of veno-occlusive disease",
                    "timeFrame": "From first HSCT conditioning dose until 100 days post-HSCT"
                },
                {
                    "measure": "Impact of olanzapine on HSCT outcomes on incidence of GVHD",
                    "description": "Looking at incidence of GVHD between the two arms",
                    "timeFrame": "From first HSCT conditioning dose until 100 days post-HSCT"
                },
                {
                    "measure": "Impact of olanzapine on HSCT outcomes on severity of GVHD",
                    "description": "Comparing the incidence of the different maximal grades of GVHD between the two arms",
                    "timeFrame": "From first HSCT conditioning dose until 100 days post-HSCT"
                },
                {
                    "measure": "Association between PeNAT and MASCC Antiemesis Tool (MAT) scores",
                    "description": "taking maximum daily PeNAT scale score and maximum nausea experience in MAT will estimate the degree of association between PeNAT and MAT",
                    "timeFrame": "up to 1 month"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Planned receipt of HEC or cyclophosphamide \u2265 1 g/m2/day (\u2265 33 mg/kg/day) for cancer treatment or autologous or allogeneic HSCT conditioning.81,82 Examples of HEC are: busulfan IV (myeloablative dosing), carboplatin \u2265175mg/m\u00b2/dose, cisplatin \u226512mg/m\u00b2/dose, cytarabine \u22653g/m\u00b2/day, melphalan \\>140mg/m\u00b2, methotrexate \u226512g/m\u00b2/dose and thiotepa \u2265300mg/m\u00b2/dose.\n\nPlan for inpatient admission from administration of first study drug dose until 24 hours following administration of last study drug dose.\n\nBody weight of at least 12.5 kg\n\n2.5 to \\< 18 years of age. Note that the minimum age requirement corresponds to an approximate body weight of 12.5 kg.\n\nSamples for all laboratory tests will be obtained within one week prior to administration of the first chemotherapy dose of the study chemotherapy block or the first HSCT conditioning dose:\n\n* Plasma creatinine within 1.5 times the upper limit of normal for age.\n* Amylase within age-appropriate limits\n* Plasma conjugated bilirubin within \u2264 3x upper limit of normal for age unless attributable to Gilbert's Syndrome\n* ALT \u2264 5x upper limit of normal for age\n\nBaseline ECG within the month prior to study drug administration without known clinically significant abnormalities including pathologic prolongation of QTc\n\nA plan for scheduled, round-the-clock receipt of ondansetron, granisetron or palonosetron for antiemetic prophylaxis during administration of chemotherapy or HSCT conditioning.\n\nNegative pregnancy test if female of childbearing potential\n\nPatients of childbearing potential must consent to use adequate contraception (males and females) or agree to practice abstinence\n\nParent or child able to speak a language in which the (modified Pediatric Adverse Event Rating Scale (PAERS) is available.\n\nOptional: Child participants in the optional assessment of nausea severity must be 4 to 18 years of age. Child and a parent/guardian must be English, Spanish or French-speaking. The Pediatric Nausea Assessment Tool58 (PeNAT) is validated in English-speaking children 4 to 18 years old with an English-speaking parent/guardian and has been translated into Spanish and French. The MAT is available in English, Spanish and French.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "30 Months",
            "maximumAge": "18 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lee Dupuis, RPh, PhD",
                    "role": "CONTACT",
                    "phone": "416-813-7762",
                    "email": "lee.dupuis@sickkids.ca"
                },
                {
                    "name": "Muhammad Ali, MD",
                    "role": "CONTACT",
                    "phone": "416-813-7654",
                    "phoneExt": "201438",
                    "email": "muhammad.ali@sickkids.ca"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Lee Dupuis, RPh, PhD",
                    "affiliation": "The Hospital for Sick Children",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Muhammad Ali, MD",
                    "affiliation": "The Hospital for Sick Children",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ying Lu",
                            "role": "CONTACT",
                            "email": "ying.lu@ucsf.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "The Children's Mercy Hospital",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Missouri",
                    "zip": "64108",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Judy Vun",
                            "role": "CONTACT",
                            "phone": "816-302-6797"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.09973,
                        "lon": -94.57857
                    }
                },
                {
                    "facility": "Columbia University/Morgan Stanley Children's Hospital",
                    "status": "WITHDRAWN",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of North Carolina at Chapel Hill",
                    "status": "RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27599-7220",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Juanita Cuffee",
                            "role": "CONTACT",
                            "phone": "919-966-0017",
                            "email": "cuffee@med.unc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "Nationwide Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43205",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clelie Peck",
                            "role": "CONTACT",
                            "email": "clelie.peck@nationwidechildrens.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "Medical University of South Carolina",
                    "status": "RECRUITING",
                    "city": "Charleston",
                    "state": "South Carolina",
                    "zip": "29425",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shanta Salzer",
                            "role": "CONTACT",
                            "phone": "843-792-1463"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.77657,
                        "lon": -79.93092
                    }
                },
                {
                    "facility": "Cancer Care Manitoba",
                    "status": "RECRUITING",
                    "city": "Winnipeg",
                    "state": "Manitoba",
                    "zip": "R3E 0V9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Kathy Hjalmarsson",
                            "role": "CONTACT",
                            "email": "khjalmarsson@cancercare.mb.ca"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.8844,
                        "lon": -97.14704
                    }
                },
                {
                    "facility": "Hospital for Sick Children",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 1X8",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Lee Dupuis, PhD",
                            "role": "CONTACT",
                            "phone": "416-813-7654",
                            "phoneExt": "309355",
                            "email": "lee.dupuis@sickkids.ca"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Centre Hospitalier Universitaire Sainte-Justine,",
                    "status": "TERMINATED",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "zip": "H3T 1C5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "All India Institute of Medical Sciences",
                    "status": "RECRUITING",
                    "city": "New Delhi",
                    "state": "Delhi",
                    "zip": "110029",
                    "country": "India",
                    "contacts": [
                        {
                            "name": "Shuvadeep Ganguly",
                            "role": "CONTACT",
                            "email": "Ganguly.Shuvadeep@gmail.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.63576,
                        "lon": 77.22445
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "16945043",
                    "type": "BACKGROUND",
                    "citation": "Dupuis LL, Taddio A, Kerr EN, Kelly A, MacKeigan L. Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents. Pharmacotherapy. 2006 Sep;26(9):1221-31. doi: 10.1592/phco.26.9.1221."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014839",
                    "term": "Vomiting"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012817",
                    "term": "Signs and Symptoms, Digestive"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17582",
                    "name": "Vomiting",
                    "asFound": "Vomiting",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12273",
                    "name": "Nausea",
                    "relevance": "LOW"
                },
                {
                    "id": "M15622",
                    "name": "Signs and Symptoms, Digestive",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077152",
                    "term": "Olanzapine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000014150",
                    "term": "Antipsychotic Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000017367",
                    "term": "Selective Serotonin Reuptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1675",
                    "name": "Olanzapine",
                    "asFound": "Field",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M7805",
                    "name": "Emetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M16904",
                    "name": "Antipsychotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "relevance": "LOW"
                },
                {
                    "id": "M19649",
                    "name": "Selective Serotonin Reuptake Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Emet",
                    "name": "Emetics"
                }
            ]
        }
    },
    "hasResults": false
}